Journal of Current Glaucoma Practice

Register      Login

VOLUME 14 , ISSUE 3 ( September-December, 2020 ) > List of Articles

Original Article

Combined Technique for the Application of Micropulse Cyclophotocoagulation in Patients with Uncontrolled Glaucoma: Cyclo Mix

Loayza-Gamboa Waldo, Herrera-Quiroz Julio, Chávez-Vallejos Jennifer, Valderrama-Albino Vanessa, Córdova-Crisanto Luis, Alvarado-Villacorta Rosa, Valera-Cornejo Diego Alejandro

Citation Information : Waldo L, Julio H, Jennifer C, Vanessa V, Luis C, Rosa A, Alejandro VD. Combined Technique for the Application of Micropulse Cyclophotocoagulation in Patients with Uncontrolled Glaucoma: Cyclo Mix. J Curr Glaucoma Pract 2020; 14 (3):93-97.

DOI: 10.5005/jp-journals-10078-1289

License: CC BY-NC 4.0

Published Online: 01-12-2020

Copyright Statement:  Copyright © 2020; The Author(s).


Purpose: To describe the outcomes of a combined technique (Cyclo Mix) in uncontrolled glaucoma cases. Materials and methods: Retrospective study. The Supra 810 nm subliminal laser (Quantel Medical, Cournon d’Auvergne, France) was used. A combined technique was performed using the subliminal mode (Subcyclo) in one hemifield (power of 2,000 mW, a duty cycle of 35%, and 80–150 seconds), and the continuous wave mode (Thermo Cyclo) on the other hemifield (power of 1,000 mW, exposure time of 2 seconds per spot). The primary endpoint was the probability of surgical failure. Mean intraocular pressure (IOP) change, best-corrected visual acuity (BCVA), number of glaucoma eye drops, and complications at 6 months postoperatively were secondary outcomes. Results: Twenty-three eyes from 13 patients were included. Mean age was 61.4 ± 16.7 (range: 18–78 years), and 69% were female, with a baseline IOP of 20.3 ± 5.9 (range: 13–38 mm Hg). The cumulative probability of failure was 18 and 22% on days 90 and 180, respectively. Mean IOP reduction was −25.6 ± 20.9% at 6 months. The number of glaucoma eye drops was reduced to 1.2 ± 1 (p = 0.0024) at 6 months. No statistically significant change in the mean BCVA compared with baseline at 6 months was found (p = 0.84), and no severe complications were reported. Conclusion: Cyclo Mix seems to be a safe therapy that effectively reduces the IOP and glaucoma medications in eyes with uncontrolled open-angle glaucoma for up to 6 months.

  1. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol Chic Ill 1960 2003;121(1):48–56. DOI: 10.1001/archopht.121.1.48.
  2. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121(11):2081–2090. DOI: 10.1016/j.ophtha.2014.05.013.
  3. The AGIS Investigators. Am J Ophthalmol 2000;130(4):429–440. DOI: 10.1016/S0002-9394(00)00538-9.
  4. Primary open-angle glaucoma. Lancet Lond Engl 2004;363(9422):1711–1720. DOI: 10.1016/S0140-6736(04)16257-0.
  5. Die zyklodiatermie das corpus ciliare bei glaukom. Zentralbl Ophthalmol 1933;29:562–569.
  6. Diode lasers in photomedicine. IEEE J Quantum Electron 1984;20(12):1433–1439. DOI: 10.1109/JQE.1984.1072352.
  7. Semiconductor diode laser transscleral cyclophotocoagulation in patients with glaucoma. Am J Ophthalmol 1992;113(1):81–85. DOI: 10.1016/S0002-9394(14)75758-7.
  8. Choroidal detachment, flat anterior chamber, and hypotony as complications of neodymium: YAG laser cyclophotocoagulation. Ophthalmology 1990;97(1):69–72. DOI: 10.1016/S0161-6420(90)32640-4.
  9. Long-term efficacy and visual acuity following transscleral diode laser photocoagulation in cases of refractory and non-refractory glaucoma. Eye Lond Engl 2007;21(7):936–940. DOI: 10.1038/sj.eye.6702345.
  10. Micropulse laser for the treatment of glaucoma: a literature review. Surv Ophthalmol 2019;64(4):486–497. DOI: 10.1016/j.survophthal.2019.01.001.
  11. Clinical efficacy and safety profile of micropulse transscleral cyclophotocoagulation in refractory glaucoma. J Glaucoma 2018;27(5):445–449. DOI: 10.1097/IJG.0000000000000934.
  12. Safety and efficacy of diode laser transscleral cyclophotocoagulation in eyes with good visual acuity. J Glaucoma 2018;27(10):874–879. DOI: 10.1097/IJG.0000000000001057.
  13. Micropulse cyclophotocoagulation: initial results in refractory glaucoma. J Glaucoma 2017;26(8):726–729. DOI: 10.1097/IJG.0000000000000715.
  14. Plus: a modified micropulse transscleral cyclophototherapy technique for the treatment of refractory glaucoma. J Glaucoma 2020;29(4):264–270. DOI: 10.1097/IJG.0000000000001443.
  15. Comparative effectiveness and tolerance of subliminal subthreshold transscleral cyclophotocoagulation with a duty factor of 25% versus 31.3% for advanced glaucoma. J Glaucoma 2020;29(2):97–103. DOI: 10.1097/IJG.0000000000001409.
  16. Consensus on definition of success. Text book of guidelines on design and reporting of glaucoma surgical trials. World Glaucoma Association. The Netherlands: Kugler Publications; 2009. pp. 18–24.
  17. Micropulse versus continuous wave transscleral diode cyclophotocoagulation in refractory glaucoma: a randomized exploratory study. Clin Experiment Ophthalmol 2015;43(1):40–46. DOI: 10.1111/ceo.12360.
  18. Micropulse transscleral diode laser cyclophotocoagulation in the treatment of refractory glaucoma. Clin Experiment Ophthalmol 2010;38(3):266–272. DOI: 10.1111/j.1442-9071.2010.02238.x.
  19. Outcomes of micropulse transscleral cyclophotocoagulation in uncontrolled glaucoma patients. J Glaucoma 2019;28(3):270–275. DOI: 10.1097/IJG.0000000000001174.
  20. Transcleral laser induces aqueous outflow pathway motion & reorganization. In Coronado, CA 2017 American Glaucoma Society Meeting.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.